Jonca Bull Brings Clinical Experience To FDA Minority Health Office
This article was originally published in The Pink Sheet Daily
Bull returns to the agency after stints at Novartis and Genentech to become director of the Office of Minority Health.
You may also be interested in...
PhRMA takes an active role in shaping a new National Clinical Trial Network that aims to speed up enrollment of diverse study populations as FDA increases its push for minorities in clinical research.
Vertex Pharmaceuticals' Incivek (telaprevir) has cleared FDA with labeling advantages that should enable it to win a majority of patients in the battle against Merck's competing protease inhibitor for hepatitis C, Victrelis (boceprevir).
The indication is notable for what it does not contain, which is language specifically excluding African Americans or patients with severe active lupus nephritis or severe central nervous system lupus.